These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 37847858)

  • 1. Epstein-Barr virus-encoded EBNA2 downregulates ICOSL by inducing miR-24 in B-cell lymphoma.
    Leopizzi M; Mundo L; Messina E; Campolo F; Lazzi S; Angeloni A; Marchese C; Leoncini L; Giordano C; Slack F; Trivedi P; Anastasiadou E
    Blood; 2024 Feb; 143(5):429-443. PubMed ID: 37847858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas.
    Anastasiadou E; Stroopinsky D; Alimperti S; Jiao AL; Pyzer AR; Cippitelli C; Pepe G; Severa M; Rosenblatt J; Etna MP; Rieger S; Kempkes B; Coccia EM; Sui SJH; Chen CS; Uccini S; Avigan D; Faggioni A; Trivedi P; Slack FJ
    Leukemia; 2019 Jan; 33(1):132-147. PubMed ID: 29946193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EBNA2-deleted Epstein-Barr virus (EBV) isolate, P3HR1, causes Hodgkin-like lymphomas and diffuse large B cell lymphomas with type II and Wp-restricted latency types in humanized mice.
    Li C; Romero-Masters JC; Huebner S; Ohashi M; Hayes M; Bristol JA; Nelson SE; Eichelberg MR; Van Sciver N; Ranheim EA; Scott RS; Johannsen EC; Kenney SC
    PLoS Pathog; 2020 Jun; 16(6):e1008590. PubMed ID: 32542010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancer Control of MicroRNA miR-155 Expression in Epstein-Barr Virus-Infected B Cells.
    Wood CD; Carvell T; Gunnell A; Ojeniyi OO; Osborne C; West MJ
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30021904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Latent Epstein-Barr virus infection collaborates with Myc over-expression in normal human B cells to induce Burkitt-like Lymphomas in mice.
    Bristol JA; Nelson SE; Ohashi M; Casco A; Hayes M; Ranheim EA; Pawelski AS; Singh DR; Hodson DJ; Johannsen EC; Kenney SC
    PLoS Pathog; 2024 Apr; 20(4):e1012132. PubMed ID: 38620028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus EBNA2 directs doxorubicin resistance of B cell lymphoma through CCL3 and CCL4-mediated activation of NF-κB and Btk.
    Kim JH; Kim WS; Hong JY; Ryu KJ; Kim SJ; Park C
    Oncotarget; 2017 Jan; 8(3):5361-5370. PubMed ID: 28036258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential regulation of miR-21 and miR-146a by Epstein-Barr virus-encoded EBNA2.
    Rosato P; Anastasiadou E; Garg N; Lenze D; Boccellato F; Vincenti S; Severa M; Coccia EM; Bigi R; Cirone M; Ferretti E; Campese AF; Hummel M; Frati L; Presutti C; Faggioni A; Trivedi P
    Leukemia; 2012 Nov; 26(11):2343-52. PubMed ID: 22614176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EBNA2 interferes with the germinal center phenotype by downregulating BCL6 and TCL1 in non-Hodgkin's lymphoma cells.
    Boccellato F; Anastasiadou E; Rosato P; Kempkes B; Frati L; Faggioni A; Trivedi P
    J Virol; 2007 Mar; 81(5):2274-82. PubMed ID: 17151114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23.
    Cordier M; Calender A; Billaud M; Zimber U; Rousselet G; Pavlish O; Banchereau J; Tursz T; Bornkamm G; Lenoir GM
    J Virol; 1990 Mar; 64(3):1002-13. PubMed ID: 2154588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr Virus Infection of Cell Lines Derived from Diffuse Large B-Cell Lymphomas Alters MicroRNA Loading of the Ago2 Complex.
    Ayoubian H; Ludwig N; Fehlmann T; Menegatti J; Gröger L; Anastasiadou E; Trivedi P; Keller A; Meese E; Grässer FA
    J Virol; 2019 Feb; 93(3):. PubMed ID: 30429351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Europe expression of EBNA2 is associated with poor survival in EBV-positive diffuse large B-cell lymphoma of the elderly.
    Stuhlmann-Laeisz C; Borchert A; Quintanilla-Martinez L; Hoeller S; Tzankov A; Oschlies I; Kreuz M; Trappe R; Klapper W
    Leuk Lymphoma; 2016; 57(1):39-44. PubMed ID: 25899404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA2) target proteins by proteome analysis: activation of EBNA2 in conditionally immortalized B cells reflects early events after infection of primary B cells by EBV.
    Schlee M; Krug T; Gires O; Zeidler R; Hammerschmidt W; Mailhammer R; Laux G; Sauer G; Lovric J; Bornkamm GW
    J Virol; 2004 Apr; 78(8):3941-52. PubMed ID: 15047810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Counteracting effects of cellular Notch and Epstein-Barr virus EBNA2: implications for stromal effects on virus-host interactions.
    Rowe M; Raithatha S; Shannon-Lowe C
    J Virol; 2014 Oct; 88(20):12065-76. PubMed ID: 25122803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EBNA2-EBF1 complexes promote MYC expression and metabolic processes driving S-phase progression of Epstein-Barr virus-infected B cells.
    Beer S; Wange LE; Zhang X; Kuklik-Roos C; Enard W; Hammerschmidt W; Scialdone A; Kempkes B
    Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2200512119. PubMed ID: 35857872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An EBNA3A-Mutated Epstein-Barr Virus Retains the Capacity for Lymphomagenesis in a Cord Blood-Humanized Mouse Model.
    Romero-Masters JC; Ohashi M; Djavadian R; Eichelberg MR; Hayes M; Zumwalde NA; Bristol JA; Nelson SE; Ma S; Ranheim EA; Gumperz JE; Johannsen EC; Kenney SC
    J Virol; 2020 May; 94(10):. PubMed ID: 32132242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis.
    Zhao CX; Yan ZX; Wen JJ; Fu D; Xu PP; Wang L; Cheng S; Hu JD; Zhao WL
    Mol Cancer; 2021 Dec; 20(1):153. PubMed ID: 34852843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A20 (TNFAIP3) deletion in Epstein-Barr virus-associated lymphoproliferative disorders/lymphomas.
    Ando M; Sato Y; Takata K; Nomoto J; Nakamura S; Ohshima K; Takeuchi T; Orita Y; Kobayashi Y; Yoshino T
    PLoS One; 2013; 8(2):e56741. PubMed ID: 23418597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EBV-miR-BHRF1-2 targets PRDM1/Blimp1: potential role in EBV lymphomagenesis.
    Ma J; Nie K; Redmond D; Liu Y; Elemento O; Knowles DM; Tam W
    Leukemia; 2016 Mar; 30(3):594-604. PubMed ID: 26530011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Notch1, Notch2, and Epstein-Barr virus-encoded nuclear antigen 2 signaling differentially affects proliferation and survival of Epstein-Barr virus-infected B cells.
    Kohlhof H; Hampel F; Hoffmann R; Burtscher H; Weidle UH; Hölzel M; Eick D; Zimber-Strobl U; Strobl LJ
    Blood; 2009 May; 113(22):5506-15. PubMed ID: 19339697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus detection in non-Hodgkin's lymphoma of the oral cavity: an immunocytochemical and in situ hybridization study.
    Leong IT; Fernandes BJ; Mock D
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Aug; 92(2):184-93. PubMed ID: 11505266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.